Galán I - Search Results

1

Significant clinical worsening after natalizumab withdrawal: Predictive factors.

Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, Nos C, Arrambide G, Comabella M, Galán I, Castilló J, Sastre-Garriga J, Rovira A, Montalban X. Vidal-Jordana A, et al. Among authors: galan i. Mult Scler. 2015 May;21(6):780-5. doi: 10.1177/1352458514549401. Epub 2014 Nov 12. Mult Scler. 2015. PMID: 25392320

2

[Interobserver variability in the evaluation of functional systems and Kurzke expanded disability status scale in a multiple sclerosis patient].

Montalban X, Tintoré M, Río J, Galán I, Codina A. Montalban X, et al. Among authors: galan i. Rev Neurol. 1996 Jun;24(130):630-2. Rev Neurol. 1996. PMID: 8653604 Spanish.

3

Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis.

Acarín N, Río J, Fernández AL, Tintoré M, Durán I, Galán I, Montalban X. Acarín N, et al. Among authors: galan i. Acta Neurol Scand. 1996 Feb-Mar;93(2-3):99-103. doi: 10.1111/j.1600-0404.1996.tb00182.x. Acta Neurol Scand. 1996. PMID: 8741126

4

[Descriptive study of first visits in a multiple sclerosis specialised unit].

Sastre-Garriga J, Río J, Nos C, Galán I, Tintoré M, Montalbán X. Sastre-Garriga J, et al. Among authors: galan i. Neurologia. 2002 Apr;17(4):179-82. Neurologia. 2002. PMID: 11940405 Spanish.

5

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.

Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X. Río J, et al. Among authors: galan i. Ann Neurol. 2002 Oct;52(4):400-6. doi: 10.1002/ana.10290. Ann Neurol. 2002. PMID: 12325067 Clinical Trial.

6

[Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis].

Río J, Tintoré M, Téllez N, Nos C, Galán I, Montalbán X. Río J, et al. Among authors: galan i. Med Clin (Barc). 2005 Feb 5;124(4):140-1. doi: 10.1157/13071005. Med Clin (Barc). 2005. PMID: 15713243 Spanish.

7

Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.

Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X. Río J, et al. Among authors: galan i. J Neurol. 2005 Jul;252(7):795-800. doi: 10.1007/s00415-005-0748-5. Epub 2005 Mar 18. J Neurol. 2005. PMID: 15772741 Clinical Trial.

8

Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?

Téllez N, Río J, Tintoré M, Nos C, Galán I, Montalban X. Téllez N, et al. Among authors: galan i. Mult Scler. 2005 Apr;11(2):198-202. doi: 10.1191/1352458505ms1148oa. Mult Scler. 2005. PMID: 15794395

9

Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.

Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X. Río J, et al. Among authors: galan i. Ann Neurol. 2006 Feb;59(2):344-52. doi: 10.1002/ana.20740. Ann Neurol. 2006. PMID: 16437558 Clinical Trial.

10

Fatigue in multiple sclerosis persists over time: a longitudinal study.

Téllez N, Río J, Tintoré M, Nos C, Galán I, Montalban X. Téllez N, et al. Among authors: galan i. J Neurol. 2006 Nov;253(11):1466-70. doi: 10.1007/s00415-006-0247-3. Epub 2006 Jun 13. J Neurol. 2006. PMID: 16773265

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235 results

Search Page

Filters